ArticleSurgical endoscopy2015
Serum value of procalcitonin as a marker of intestinal damages: type, extension, and prognosis.
Article in Surgical endoscopy, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Diagnostic accuracy of routine hematological biomarkers for complications and prognosis in bowel obstruction: a systematic review and meta-analysis.World journal of emergency surgery : WJES · 2025Pooled it
- Impact of a procalcitonin-based algorithm on the quality of management of patients with uncomplicated adhesion-related small bowel obstruction assessed by a textbook outcome: a multicenter cluster-randomized open-label controlled trial.BMC gastroenterology · 2022Trial
- Precision medicine in intestinal ischemia: the emerging role of biomarkers.Internal and emergency medicine · 2025Review
- C-reactive protein and digestive pathologies: A narrative review for daily clinical use.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025Review
- Comprehensive Analysis of the Correlation Between Immune-Inflammatory Biomarkers and Intestinal Necrosis in Patients With Acute Intestinal Ischemia.Mediators of inflammation · 2025Article
- Outcomes after open and endovascular treatment for mesenteric artery embolism patients: a retrospective inverse probability of treatment-weighted analysis.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2024Article
- The Efficiency of Serum Biomarkers in Predicting the Clinical Outcome of Patients with Mesenteric Ischemia during Follow-Up: A Systematic Review.Diagnostics (Basel, Switzerland) · 2024Review
- Review
- Improving clinical suspicion of acute mesenteric ischemia among patients with acute abdomen: a cross-sectional study from an intestinal stroke center.World journal of emergency surgery : WJES · 2023Article
- Biomarkers of Intestinal Injury in Colic.Animals : an open access journal from MDPI · 2023Review
- Clinico-bacterial and prognostic factors in patients with suspected blood stream infection and elevated serum procalcitonin levels.Nagoya journal of medical science · 2022Article
- Reappraisal of ischemia-reperfusion injury in a short duration laparoscopic surgery, a pilot study.BMC surgery · 2021Article
- Non-occlusive mesenteric ischemia: Diagnostic challenges and perspectives in the era of artificial intelligence.World journal of gastroenterology · 2021Review
- Stromal cell-derived factor-1 as a serologic biomarker for the diagnosis of colon ischemia with chronic cardiovascular disease.Medicine · 2020Article
- Biochemical markers of acute intestinal ischemia: possibilities and limitations.Annals of translational medicine · 2018Review
- Biological scoring system for early prediction of acute bowel ischemia after cardiac surgery: the PALM score.Annals of intensive care · 2018Article
- Predictive Factors of Intestinal Necrosis in Acute Mesenteric Ischemia: Prospective Study from an Intestinal Stroke Center.The American journal of gastroenterology · 2017Observational
- New biomarkers for outcomes of acute mesenteric ischemia.Intensive care medicine · 2015Article
- Acute mesenteric ischemia, procalcitonin, and intensive care unit.Intensive care medicine · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIschemic and necrotic damages are complications of digestive diseases and require emergency management. Nevertheless, the decision to surgically manage could be delayed because of no sufficiently preoperative accurate marker of ischemia diagnosis, extension, and prognosis.
methodsThe aim of this study was to assess the predictive value of serum procalcitonin (PCT) levels for diagnosing intestinal necrotic damages, their extension, and their prognosis in patients with ischemic disease including ischemic colitis and mesenteric infarction by a gray zone approach. Between January 2007 to June 2014, 128 patients with ischemic colitis and mesenteric infarction (codes K55.0 and K51.9) were operated, for whom data on PCT were available. We perform a retrospective, multicenter review of their medical records. Patients were divided into subgroups: ischemia (ID group) versus necrosis (ND group); the extension [focal (FD) vs. extended (ED)] and the vital status [deceased (D) vs. alive (A)].
resultsPCT levels were higher in the ND (n = 94; p = 0.009); ED (n = 100; p = 0.02); and D (n = 70; p = 0.0003) groups. With a gray zone approach, the predictive thresholds were (i) for necrosis 2.473 ng/mL, (ii) for extension 3.884 ng/mL, and (iii) for mortality 7.87 ng/mL.
conclusionIn our population, PCT could be used as a marker of necrosis; especially in case of extended damages and reflects the patient's prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.